PLCD1 is a functional tumor suppressor inducing G2/M arrest and frequently methylated in breast cancer

PLCD1 is a functional tumor suppressor inducing G2/M arrest and frequently methylated in breast cancer
复制标题

DOI:
10.4161/cbt.10.5.12726
复制
发表时间:
2010-09-01
影响因子:
3.6
通讯作者:
Ren, Guosheng
Ren, Guosheng
中科院分区:
医学3区
文献类型:
--
作者:
Xiang, Tingxiu;Li, Lili;Ren, Guosheng

文献摘要

被引文献

相似文献

3p 染色体含有多个肿瘤抑制基因。 PLCD1 位于 3p22,编码一种酶,可介导能量代谢、钙稳态和细胞内运动的调节信号传导。我们研究了 PLCD1 的表观遗传改变及其在乳腺癌中的肿瘤抑制功能。通过使用半定量 PCR,发现大多数乳腺癌细胞系中 PLCD1 频繁下调/沉默。通过甲基化特异性PCR(MSP),在78%(7/9)的细胞系和52%(13/25)的原发性肿瘤中检测到PLCD1启动子甲基化,但在任何肿瘤邻近乳腺组织和正常乳腺组织中均未检测到,这一点通过亚硫酸氢盐基因组测序(BGS)进一步证实。 PLCD1 的沉默可以通过药理学去甲基化来逆转,表明甲基化介导的机制。 PLCD1在沉默的乳腺癌细胞中的异位表达显着抑制了它们的集落形成。此外,PLCD1 抑制肿瘤细胞迁移并诱导细胞周期 G(2)/M 停滞。因此,这项研究首次证明了PLCD1在乳腺癌中因启动子甲基化而频繁失活及其肿瘤抑制功能。 PLCD1 的肿瘤特异性甲基化可能作为乳腺癌早期检测和预后预测的生物标志物。
Chromosome 3p harbors multiple tumor-suppressor genes. PLCD1, located at 3p22, encodes an enzyme that mediates regulatory signaling of energy metabolism, calcium homeostasis and intracellular movement. We investigated the epigenetic alterations of PLCD1 and its tumor suppressor function in breast cancer. Frequent downregulation/silencing of PLCD1 was shown in most breast cancer cell lines by using semi-quantitative PCR. Promoter methylation of PLCD1 was detected in 78% (7/9) of cell lines and 52% (13/25) of primary tumors by Methylation-specific PCR (MSP), but not in any tumor adjacent breast tissues and normal breast tissues, which was further confirmed by bisulfite genomic sequencing (BGS). The silencing of PLCD1 could be reversed by pharmacological demethylation, indicating a methylation-mediated mechanism. Ectopic expression of PLCD1 in silenced breast cancer cells significantly inhibited their colony formation. In addition, PLCD1 inhibited tumor cell migration and induced cell cycle G(2)/M arrest. Thus, this study for the first time demonstrates the frequent inactivation of PLCD1 by promoter methylation and its tumor inhibitory function in breast cancer. Tumor-specific methylation of PLCD1 might serve as a biomarker for possible early detection and prognosis prediction of breast cancer.